ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Apellis Initiates Study of APL-9 in Patients with Severe COVID-19
June 04, 2020Apellis Pharmaceuticals announced the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions ... -
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 12, 2019Citigroup, J.P. Morgan and Cowen acted as joint book-running managers for the offering. Cantor Fitzgerald & Co. acted as lead manager for the offering.
Pharma Sources Insight January 2025
